Lexicon Pharmaceuticals Inc (LXRX) saw an uptrend of 3227150% in the recent trading with $13400000.0 being its most recent. The current price level -68.56% lower than the highest price of $2.45 marked by the stock while trading over the past 52-weeks, whereas it is 171.61% higher than the lowest price of $0.28 the company dropped to over past 52-weeks. The latest news story on LXRX appeared in (GlobeNewswire) under the title “Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)” on Jun-23-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.
Lexicon Pharmaceuticals Inc Earnings – What Happened With LXRX
Coming around sales and income figures on LXRX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Lexicon Pharmaceuticals Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 363.18 million. LXRX does have institutional investors; and they hold 26.54% of the stock.
As on 2024-06-30, ARTAL GROUP S.A. was the top most holder in Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) with an ownership of 175.1 million shares of the company or 56.3318 of the stake worth $294.17 million. The filing also reveals FMR LLC as the second largest holder in the company with a control over 12.4462 of the outstanding shares. Its stake is worth $64.99 million for having 38.69 million shares in hand.
BLACKROCK INC. also came holding a key position in the company during the recent quarter and it now holds 3.1818 of the outstanding shares. With this there are now 165.0 institutions which have possession in LXRX’s shares.
Key Metrics forLXRX
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Lexicon Pharmaceuticals Inc has a debt to equity ratio of 0.86.
Technical Analysis of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Lexicon Pharmaceuticals Inc (LXRX), we notice that the stock’s 20-day average volume is at 3,682,840 shares and 50% of short term indicators are suggesting the stock as Buy. And to end with, LXRX’s 100-day average volume are 10,996,352 shares.
